Intas

Intas Pharmaceuticals Limited, commonly known as Intas, is a privately held Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, India. Founded in 1977 by Hasmukh Chudgar, Intas has grown to become one of India's largest privately owned pharmaceutical firms. The company reported a revenue of approximately $2.4 billion USD for the fiscal year ending March 2024 and employs over 23,000 individuals as of December 2025. The Chudgar family maintains a majority ownership stake, with minority investments from entities like Temasek Holdings, Abu Dhabi Investment Authority (ADIA), and ChrysCapital.

Intas specializes in the formulation development, manufacturing, and marketing of generic drugs and biosimilars across a wide range of therapeutic areas, including oncology, nephrology, diabetology, and central nervous system disorders. The company's product portfolio also encompasses active pharmaceutical ingredients (API), oral solid dosages, injectables, and plasma products. With 22 manufacturing plants globally, primarily in India, the UK, and Mexico, Intas exports its products to over 85 countries through vertically integrated operations and subsidiaries such as Accord Healthcare.

In terms of patent litigation, Intas Pharmaceuticals Limited exhibits the posture of an operating company defending against patent infringement claims. The company has a record of one tracked case as a defendant and zero as a plaintiff. This indicates that Intas is primarily targeted in intellectual property disputes rather than initiating them.

The sole tracked case involving Intas Pharmaceuticals is Veloxis Pharmaceuticals, Inc. v. Accord Healthcare et al. in the Delaware District Court. [case data] This case highlights litigation where Intas, likely through its subsidiary Accord Healthcare, is a defendant, which is consistent with an operating company defending its product offerings in the market. [case data]